We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSLN
RNS Number : 9678M
Silence Therapeutics PLC
03 August 2017
Director/PDMR Shareholding
3 August 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it was advised on 2 August that on that day Alistair Gray, a Non-Executive Director of the Company bought 3,848 Ordinary Shares at 129.75p.
Following this purchase, Alistair Gray is interested in 3,848 ordinary shares, 0.01% of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities (PDMR) / person closely associated --- --------------------------------------------------------------- a) Name Alistair Gray --- --------------------- ---------------------------------------- 2. Reason for the notification --- --------------------------------------------------------------- a) Position / PDMR - Non-Executive Director status --- --------------------- ---------------------------------------- b) Initial notification Initial notification / Amendment --- --------------------- ---------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- --------------------------------------------------------------- a) Name Silence Therapeutics plc --- --------------------- ---------------------------------------- b) LEI 213800SSURRJBX85SQ91 --- --------------------- ---------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- --------------------------------------------------------------- a) Description Ordinary Shares in Silence Therapeutics of the financial plc instrument, type of instrument Identification ISIN for Silence Therapeutics plc code Ordinary Shares: GB00B9GTXM62 --- --------------------- ---------------------------------------- b) Nature of the Purchase of Ordinary Shares in transaction Silence Therapeutics plc --- --------------------- ---------------------------------------- c) Prices(a) and Price Volume volume(s) -------- ------- 129.75p 3,848 -------- ------- --- --------------------- ---------------------------------------- d) Aggregated information 3,848 Ordinary Shares - Aggregated GBP4,993 volume - Price --- --------------------- ---------------------------------------- e) Date of the 2 August 2017 transaction --- --------------------- ---------------------------------------- f) Place of the London Stock Exchange, AIM transaction --- --------------------- ----------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 Ali Mortazavi, Chief Executive Officer 3457 6900 David Ellam, Chief Financial Officer Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20 and Broker) 7418 8900 James Steel/Oliver Jackson Media Enquiries: Tel: +44 (0) FTI Consulting 20 3727 1000 Simon Conway/Brett Pollard/Stephanie Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDDGDICSGBGRD
(END) Dow Jones Newswires
August 03, 2017 02:02 ET (06:02 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions